Masimo (NASDAQ:MASI) announced today that the Dubai Health
Authority (DHA), the government organization that oversees the
healthcare systems of Dubai, is augmenting its current inventory of
Masimo equipment and technology with the implementation of Masimo
Patient SafetyNet™*, a supplemental remote monitoring and clinician
notification system, at two hospitals in Dubai.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170813005035/en/
Masimo Patient SafetyNet enables information from bedside
monitors, such as Masimo Root® with the Radical-7® or wearable
Radius-7® Pulse CO-Oximeter®, to be accessible from a central
viewing station. When changes occur in measured values, which may
indicate deterioration in a patient’s condition, Patient SafetyNet
automatically sends wireless alerts directly to clinicians,
wherever they may be. In addition, Patient SafetyNet can automate
the transfer of patient data, including admission data, vital
signs, early warning scores (EWS), and other physiological
parameters, directly to hospital electronic medical record (EMR)
systems, helping to improve clinician workflows and reduce the
possibility of transcription errors.
Dr. Andreas Taenzer and colleagues found in an 11-month study
conducted at Dartmouth-Hitchcock Medical Center that using Patient
SafetyNet and Masimo SET® pulse oximetry as part of a comprehensive
alarm management strategy reduced rescue events by 65% and
intensive care unit transfers by 48%, and as a result, reduced
costs by $1,480,000.1,2 In a subsequent article, they announced
that after five years, Dartmouth-Hitchcock had had zero preventable
deaths or instances of brain damage due to opioids since the
installation of Patient SafetyNet.2 In 2016, after ten years, they
reported achieving a 50% reduction in unplanned ICU transfers and a
60% reduction in rescue events, despite increases in patient acuity
and occupancy.3
The two Dubai Health Authority medical centers implementing
Patient SafetyNet are Dubai Hospital (625 beds), which provides
general medical and surgical care, and Latifa Hospital (367 beds),
which specializes in maternal and child care. Dubai Hospital
installed its first Patient SafetyNet in 2013. Latifa Hospital is
in the process of installing four systems, with a further system
planned for Dubai Hospital. “We are excited to deepen our
partnership with Masimo,” said Humaid Al Qatami, Chairman of the
Board and Director General of Dubai Health Authority. “The Dubai
Health Authority’s mission is to develop an integrated and
sustainable healthcare system that ensures our comprehensive
services achieve the highest international standards, and we
believe that Masimo’s monitoring devices, now even more connected
to hospital infrastructure through the power of Patient SafetyNet,
will help us meet that goal.”
“Patient SafetyNet, in conjunction with Masimo SET® pulse
oximetry, enables continuous supplemental monitoring of active
patients in post-surgical wards and can help save the lives of
patients on opioids, among many other benefits,” said Joe Kiani,
Founder and CEO of Masimo. “We applaud the Dubai Health Authority,
dedicated to providing no less than the best health care in the
world, for recognizing the importance of implementing such a proven
and powerful centralized monitoring and patient surveillance
system.”
@MasimoInnovates | #Masimo
References
- Taenzer AH et al. Impact of Pulse
Oximetry Surveillance on Rescue Events and Intensive Care Unit
Transfers: A Before-and-After Concurrence Study. Anesthesiology.
2010 Feb;112(2):282-7.
- Taenzer AH et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter Spring-Summer 2012. Available online.
- McGrath SP et al. Surveillance
Monitoring Management for General Care Units: Strategy, Design, and
Implementation. The Joint Commission Journal on Quality and Patient
Safety. 2016 Jul;42(7):293-302.
*The use of the trademark SafetyNet is under license from
University HealthSystem Consortium.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,1 improve CCHD screening in
newborns,2 and, when used for continuous monitoring with Masimo
Patient SafetyNet™* in post-surgical wards, reduce rapid response
activations and costs.3,4,5 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,6 and is the primary pulse
oximetry at 16 of the top 20 hospitals listed in the 2016-17 U.S.
News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo
introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
and more recently, Oxygen Reserve Index™ (ORi™), in addition to
SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and connectivity
platform with the Masimo Open Connect™ (MOC-9™) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7™ wearable patient
monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and
its products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available
for sale in the United States.
*The use of the trademark Patient SafetyNet is under license
from University HealthSystem Consortium.
References
- Castillo A et al. Prevention of
Retinopathy of Prematurity in Preterm Infants through Changes in
Clinical Practice and SpO2 Technology. Acta Paediatr. 2011
Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of
pulse oximetry screening on the detection of duct dependent
congenital heart disease: a Swedish prospective screening study in
39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of Pulse
Oximetry Surveillance on Rescue Events and Intensive Care Unit
Transfers: A Before-And-After Concurrence Study. Anesthesiology.
2010; 112(2):282-287.
- Taenzer AH et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance
Monitoring Management for General Care Units: Strategy, Design, and
Implementation. The Joint Commission Journal on Quality and Patient
Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Patient SafetyNet™.
These forward-looking statements are based on current expectations
about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Patient SafetyNet, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170813005035/en/
MasimoEvan Lamb, 949-396-3376elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2024 to May 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2023 to May 2024